General Characteristics
Age: 57 years
Gender: Female
Disease Origin: Sacral
Disease Status: Recurrent
Prior Radiation: No
Prior Systemic Therapy: No
Source: Beate Rinner and Bernadette Liegl, Medical University of Graz
Molecular Features
Cell Morphology: Physaliferous
TBXT Expression: Positive; 10x that of U-CH2 and with T amplification
TBXT Localization: Nuclear
CD24 Expression: Positive; 4x that of U-CH2
HLA Type: A11
Sequence Data: WGS, exome and transcriptome data available: raw sequencing data in Cavatica
(Chordoma Foundation Dataset) and summary data in PedcBioportal. Contact researchteam@chordoma.org with any questions.
SMARCB1 Status: Wild-type
Validation Results: Validation Report
Growth Conditions
Growth Medium: (4:1) IMDM/RPMI 1640 + 10% FBS + 1% NEAA + 1% GlutaMAX
Freeze Medium: 70% complete growth medium supplemented with an additional 20% fetal bovine serum and 10% DMSO
Culture Conditions: Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing Instructions: Cell Culture Procedures
Publications
Characterized By:
- Rinner B, Froehlich EV, Buerger K, Knausz H, Lohberger B et al. (2012) Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1. Int J Oncol 40(2):443-51. PubMed: 22002331.
Additional References:
- Scheipl S, Lohberger B, Rinner B, Froehlich EV, Beham A, Quehenberger F et al. Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: an immunohistochemical and functional analysis. J Orthop Res 31(12):1999-2005. PubMed: 23893747.